Harbor MedTech said yesterday that it raised nearly $5 million for the regenerative treatments for soft tissue repair it developed.
The Irvine, Calif.-based company said 3 unnamed investors participated in the equity round, which aims to raise a total of nearly $8.5 million, according to a regulatory filing.
Harbor developed a technique it calls “Bridge” to transform biologic substrates into regenerative medicine products. Its Architect stabilized collagen matrix is designed to treat complex skin wounds; the EPMatrix product is designed for surgeries to repair soft tissue injuries.
Although both products begin as highly organized Type I collagen from xenografts, the Bridge process “cleans” the grafts of intra-cellular debris and preserves extra-cellular matrix fibers, growth factors and other natural tissue proteins. The company says this improves bio-compatibility, prevents rapid degradation and encourages tissue regeneration.